NCT03972748

Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.

Evaluation Of The Treatment With Oral Itraconazole In Patients With Basocellular Carcinoma Of Skin, Locally Limited Disease.

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Hospital de Clinicas de Porto Alegre · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg twice daily, for 60 days, prior to curative intent surgery.

Detailed description

Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg once daily, for 60 days, before surgery with curative intent. Tumor area regression will be measured through dermatologic evaluation and photographic documentation on baseline and at the end of the 60 day treatment period. The activity of the Hedgehog pathway will be measured on tissue samples obtained at the time of diagnosis and at the time of curative intent surgery, through the measuring of the Ki67 index.

Conditions

• Basal Cell Carcinoma
• Hedgehog Pathway

Interventions

Type	Name	Description
DRUG	Itraconazole 200 mg	Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.

Timeline

• Start date: 2018-01-05
• Primary completion: 2020-12-01
• Completion: 2021-06-01
• First posted: 2019-06-04
• Last updated: 2019-06-04

Locations

1 site across 1 country: Brazil